68Ga-citrate PET/MR Imaging for Glioma

68Ga-citrate PET/MR Imaging for the Evaluation of Glioma in Adults

NCT03335280•Susan Chang

Summary

This is a prospective, single center, open-label study in adult patients with presumed World Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate Positron Emission Tomography / magnetic resonance (PET/MR) prior to surgery.

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•World Health Organization (WHO) grade 3 or 4 glioma planning to undergo surgery
•Age \>= 18 yrs.
•Karnofsky performance status of \>= 60
•Ability to understand a written informed consent document, and the willingness to sign it.
•Cohort A:
•\- Positive for Phosphatase and Tensin Homolog (PTEN) deletion, confirmed by immunohistochemistry of tissue biopsy
•Cohort B:
•\- Negative for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy

Exclusion Criteria

•Contraindications to Positron Emission Tomography (PET) imaging (e.g. pregnant or breast-feeding woman)
•Contraindications to magnetic resonance (MR) imaging (e.g. pacemakers, metallic implants, etc.)

Locations (1)

University of California, San Francisco

San Francisco, California, United States

Key Dates

Start Date

February 26, 2019

Primary Completion Date

April 24, 2020

Completion Date

April 24, 2020

Last Updated

May 1, 2020

Enrollment

ACTUAL participants

Conditions

Glioma

Interventions

68Ga-citrate PET/MR

DRUG

Targeted Pediatric High-Grade Glioma Therapy

NCT05839379

High Grade GliomaDiffuse Intrinsic Pontine Glioma+7 more

View study

RECRUITINGPHASE1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 1, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

68Ga-citrate PET/MR Imaging for Glioma

Inclusion Criteria

Exclusion Criteria

Targeted Pediatric High-Grade Glioma Therapy

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors